



## The Michael J. Fox Foundation for Parkinson's Research & The New York Academy of Sciences

Parkinson's Disease Therapeutics Conference New York, NY October 24, 2012

## **Poster Session on Novel Therapeutic Targets and Tools**

Lily Cappelletti, The Michael J. Fox Foundation for Parkinson's Research – "Innovative Web-based Matching Service, Fox Trial Finder, as a Mechanism to Improve Parkinson's Clinical Trial Recruitment"

Kuldip Dave, PhD, The Michael J. Fox Foundation for Parkinson's Research – "MJFF Animal Models: Phenotypic characterization of the autosomal recessive (Parkin, Pink-1 and DJ-1) gene knockout rat models of Parkinson's disease"

Jamie Eberling, PhD, The Michael J. Fox Foundation for Parkinson's Research – "The Parkinson Progression Marker Initiative (PPMI) - Baseline Data"

Martin Martinov, PhD, Gradient Biomodeling – "Identification of Nrf2 Activators Using an In Silico Modeling Platform, Followed by Evaluation of These Compounds in an Alpha-Synuclein Model of PD"

Manisha Patel, PhD, University of Colorado Denver - "Optimizing Metalloporphryins for Clinical Development"

Joel S. Perlmutter, MD, Washington University in St. Louis - "Validation of Neuroimaging Biomarkers for Nigrostriatal Neurons"

Beverly Rzigalinski, PhD, Virginia College of Osteopathic Medicine – "Cerium Oxide Nanoparticles in Treatment of Parkinson's Disease"

Yvonne Schmitz, PhD, Columbia University - "Glyt1 Inhibitors Promote Dopaminergic Striatal Sprouting"

Kathleen M. Shannon, MD, Rush Medical College - "Intestinal Permeability, Exposure to Lipopolysaccharide, and Alpha-Synuclein Aggregation in Parkinson's Disease"

David K. Simon, MD, PhD, Beth Israel Deaconess Medical Center and Harvard Medical School – "PGC-1 Alpha as a Neuroprotective Target in Parkinson's Disease"

David M. White, PhD, University of Chicago - "Oxidized DJ-1 as a Biomarker for Parkinson's Disease"